UPDATE: Biogen PRIME Results Show Slowing Of Decline On CDR-SB Was Statistically Significant With Titrated aducanumab vs. Placebo, Titration of aducanumab Appears To Reduce Incidence Of ARIA-E vs. Fixed Dosing In This Cohort